Results 81 to 90 of about 3,981,458 (213)

Heparin-induced thrombocytopenia: an update [PDF]

, 2005
Heparin-induced thrombocytopenia (HIT) is the most important and most frequent drug-induced, immune-mediated type of thrombocytopenia. It is associated with significant morbidity and mortality if unrecognized.
Franchini Massimo
core   +1 more source

Case Report: Prolonged thrombocytopenia after chemotherapy in solid tumors requiring long-term thrombopoietin receptor agonist support: a five-patient case series

Frontiers in Oncology
Chemotherapy-induced thrombocytopenia (CIT) is a clinically significant complication of systemic anticancer therapy. Although CIT is commonly classified as nadir CIT or persistent CIT based on the timing and pattern of platelet recovery, prolonged ...
Shengjie Wang, Yinan Yu, Lan Zhang, Qiuxia Liu   +3 more
doaj   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

Allergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud, Lene Heise Garvey, Elizabeth Phillips, Michael Ardern‐Jones, Sevim Bavbek, Patrizia Bonadonna, Jean‐Christoph Caubet, Ana‐Maria Copaescu, Valentina Gueli, Jose Julio Laguna, Ricardo Madrigal‐Burgaleta, Francesca Mori, Vito Sabato, Maria J Torres, Knut Brockow   +14 more
wiley   +1 more source

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres, Cristobalina Mayorga, Elizabeth J. Phillips, Adriana Ariza, Annick Barbaud, Patrizia Bonadonna, Mariana Castells, Gülfem Çelik, Knut Brockow, Lene H. Garvey, Inmaculada Doña, Jean‐Christoph Caubet, Francesca Mori, Jason Trubiano, Giorgia Marta, Antonino Romano, Ingrid Terreehorst, Asli Gelincik, Philip H. Li, Vito Sabato   +19 more
wiley   +1 more source

Review Article: Fibrosis‐4 Index in Steatotic Liver Disease—Past, Present and Future

Alimentary Pharmacology &Therapeutics, EarlyView.
FIB‐4 remains an inexpensive, scalable first‐line triage tool for excluding advanced fibrosis and identifying patients who need second‐line assessment, but it should not be used as a stand‐alone diagnostic or treatment‐selection test. Sequential testing and longitudinal FIB‐4 trajectories may improve risk stratification and prognosis.
Kriti Soni, Vinay Jahagirdar, Omar Albhaisi, Richard K. Sterling, Juan Pablo Arab, Hanna Blaney, Luis Antonio Díaz   +6 more
wiley   +1 more source

PLAG alleviates chemotherapy-induced thrombocytopenia via promotion of megakaryocyte/erythrocyte progenitor differentiation in mice

, 2018
Previously, PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol, acetylated diglyceride) was reported to have an effect on the proliferation of hematopoietic stem cells (HSCs) or to contribute to the prevention of chemotherapy-induced neutropenia.
Sun Young Yoon, Ha-Reum Lee, Jinseon Jeong, Nina Yoo, Ki-Young Sohn, K Y Sohn, Jae Wha Kim, N Yoo, S Y Yoon   +8 more
core   +1 more source

Efficacy of romiplostim therapy for hematological toxicity in patients with solid tumors

Клинический разбор в общей медицине
Background. Romiplostim is a medicinal product belonging to the group of thrombopoietin receptor agonists that has shown its efficacy and safety in treatment of immune thrombocytopenia. The number of studies focused on the efficacy of this group of drugs
Anna K. Vaskovskaia, Radion V. Tarnovsky
doaj   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

British Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne, Matthew A. Timmins, Charlotte Gaskell, Aimee Jackson, Clare Morland, Sonia Fox, Louise Hopkins, Nadia Nawaz, Susann Lehmann, Marc Wadsley, Caroline Cowley, Jacqueline Shaw, Naeem Khan, Nagesh Kalakonda, Christopher Trethewey, Ram Malladi, Paul Fields, Dima El Sharkawi, Michael Quinn, Nimish Shah, Andrew Davies, Kim Linton, Pam McKay, Rod Johnson, Simon D. Wagner, David Lewis, Graham P. Collins, Christopher P. Fox, Kate Cwynarski   +28 more
wiley   +1 more source

Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors

, 2010
Purpose and relevance. Chemotherapy-induced thrombocytopenia (CIT) can be a significant problem in patients with cancer, leading to numerous clinical complications.
Doug Steinke, Sutphin, Stephanie, Anna Hitron, Hitron, Anna, Talbert, Jeff, Amber Lawson, Adams, Val, Steinke, Doug; id_orcid, Lawson, Amber, Val Adams, Jeff Talbert, Stephanie Sutphin   +11 more
core   +1 more source

Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy

Haematologica, 2018
Severe thrombocytopenia (≤50×109 platelets/L) due to hematological malignancy and intensive chemotherapy is associated with an increased risk of clinically significant bleeding.
Constance C. F. M. J. Baaten, Floor C. J. I. Moenen, Yvonne M. C. Henskens, Frauke Swieringa, Rick J. H. Wetzels, René van Oerle, Harry F. G. Heijnen, Hugo ten Cate, Graham P. Holloway, Erik A. M. Beckers, Johan W. M. Heemskerk, Paola E. J. van der Meijden   +11 more
doaj   +1 more source